Piramal Pharma Future Growth
Future criteria checks 4/6
Piramal Pharma is forecast to grow earnings and revenue by 94.3% and 14.3% per annum respectively. EPS is expected to grow by 94.2% per annum. Return on equity is forecast to be 8.7% in 3 years.
Key information
94.3%
Earnings growth rate
94.2%
EPS growth rate
| Pharmaceuticals earnings growth | 17.7% |
| Revenue growth rate | 14.3% |
| Future return on equity | 8.7% |
| Analyst coverage | Good |
| Last updated | 30 Jan 2025 |
Recent future growth updates
Piramal Pharma Limited (NSE:PPLPHARMA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Jan 31
₹284 - That's What Analysts Think Piramal Pharma Limited (NSE:PPLPHARMA) Is Worth After These Results
Oct 26Recent updates
Piramal Pharma Limited (NSE:PPLPHARMA) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates
Jan 31₹284 - That's What Analysts Think Piramal Pharma Limited (NSE:PPLPHARMA) Is Worth After These Results
Oct 26Piramal Pharma (NSE:PPLPHARMA) Takes On Some Risk With Its Use Of Debt
Oct 25Here's Why Piramal Pharma (NSE:PPLPHARMA) Has A Meaningful Debt Burden
Jul 14Estimating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Jun 17We Think That There Are Issues Underlying Piramal Pharma's (NSE:PPLPHARMA) Earnings
May 21It's A Story Of Risk Vs Reward With Piramal Pharma Limited (NSE:PPLPHARMA)
Mar 26Estimating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Feb 28Earnings Update: Here's Why Analysts Just Lifted Their Piramal Pharma Limited (NSE:PPLPHARMA) Price Target To ₹161
Feb 02Calculating The Intrinsic Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Nov 09Calculating The Fair Value Of Piramal Pharma Limited (NSE:PPLPHARMA)
Aug 11Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 3/31/2027 | 122,747 | 8,607 | 6,961 | N/A | 7 |
| 3/31/2026 | 106,782 | 5,463 | 5,901 | N/A | 7 |
| 3/31/2025 | 93,012 | 1,282 | 1,725 | N/A | 7 |
| 12/31/2024 | 89,495 | 389 | N/A | N/A | N/A |
| 9/30/2024 | 87,038 | 453 | -310 | 6,810 | N/A |
| 6/30/2024 | 83,735 | 278 | N/A | N/A | N/A |
| 3/31/2024 | 81,712 | 178 | 2,925 | 10,045 | N/A |
| 12/31/2023 | 78,435 | -333 | N/A | N/A | N/A |
| 9/30/2023 | 76,009 | -1,336 | -992 | 8,655 | N/A |
| 6/30/2023 | 74,096 | -1,760 | N/A | N/A | N/A |
| 3/31/2023 | 70,816 | -1,865 | -4,809 | 4,839 | N/A |
| 12/31/2022 | 72,228 | -325 | -6,634 | 3,382 | N/A |
| 9/30/2022 | 69,535 | 2,210 | N/A | N/A | N/A |
| 6/30/2022 | 67,532 | 2,626 | N/A | N/A | N/A |
| 3/31/2022 | 67,341 | 3,760 | -1,231 | 7,664 | N/A |
| 3/31/2021 | 58,868 | 7,708 | -43 | 5,516 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PPLPHARMA's forecast earnings growth (94.3% per year) is above the savings rate (6.7%).
Earnings vs Market: PPLPHARMA's earnings (94.3% per year) are forecast to grow faster than the Indian market (18.1% per year).
High Growth Earnings: PPLPHARMA's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: PPLPHARMA's revenue (14.3% per year) is forecast to grow faster than the Indian market (11% per year).
High Growth Revenue: PPLPHARMA's revenue (14.3% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: PPLPHARMA's Return on Equity is forecast to be low in 3 years time (8.7%).
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/02 05:48 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Piramal Pharma Limited is covered by 14 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kunal Randeria | Axis Capital Limited |
| null null | Axis Capital Limited |
| Prakash Agarwal | Axis Capital Limited |